Drug Detail

Information about Telatinib

Generic Name	Telatinib
IND	BAY 57-9352
Brand Name (US)
Manufacturer	Bayer/ACT BIOTECH
Drug Type	Tyrosine Kinase Inhibitor
Delivery	Oral
Approval Status	Phase 2
Indications
Overall Strategy	KIT Protein Based
Strategy	Block KIT
Drug Category	KIT inhibitor

Telatinib (BAY 57-9352) is an orally available tyrosine kinase inhibitor of vascular endothelial growth factor receptor (VEGFR) -2, VEGFR-3, platelet-derived growth factor receptor beta, and c-Kit.
In a phase I trial, telatinib was safe and well tolerated up to 1,500 mg twice daily. Based on pharmacodynamic and pharmacokinetic end points, telatinib 900 mg twice daily is the recommended dose for subsequent phase II studies.
The manufacturer claims this drug may be safer (less side effects) that other drugs in this class due to a more selective target profile.